Search results
Results From The WOW.Com Content Network
Beginning January 2010 Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon. [12] [13] On March 29, 2010, Alcon acquired Durezol and Zyclorin from Sirion Therapeutics. Alcon received regulatory approval to acquire the ...
Shares of Novartis (NVS) soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon (ACL) for $12.9 billion. Novartis had been trying to gain ...
In 2010, Novartis offered to pay US$39.3 billion to fully acquire Alcon, the world's largest eye-care company, including a majority stake held by Nestlé. Novartis had bought 25 percent of Alcon in 2008. [ 38 ]
More than two years after beginning the acquisition process, Swiss pharmaceutical company Novartis ... finally completed the purchase of a 77% majority stake in U.S. eye-care company Alcon ...
As of May 2017, Novartis is estimated to be worth $193.2 billion. [29] On January 27, 2016, Alcon was moved to become a branch of the Innovative Medicines Division at Novartis. [28] Early in 2016, Alcon formed agreements with both TrueVision and PowerVision, and acquired Transcend Medical. [28]
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.